MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estima ...

MiMedx Group (MDXG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good afternoon and thank you for standing by. Welcome to the MieMedix First Quarter twenty twenty five Operating and Financial Results Conference Call. At this time, participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Matt Notariani, Head of Investor Relations for M ...

Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Florida 26-2792552 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charte ...

MIMEDX Announces First Quarter 2025 Operating and Financial Results Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Com ...

MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. MIMEDX is a pioneer and leader focused on helping humans heal. With more than a dec ...

MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. "MIMEDX's ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be on full display at these high-profile conferences ...

MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. “MIMEDX’s ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be on full display at these high-profile conferences ...

MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on va ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Bradley Bowers - Mizuho Securities Brooks O'Neil - Lake Street Capital Markets Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. ...